Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
The Lancet Haematology.
Times cited: 2
- To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma. Journal of Oncology Pharmacy Practice. 2019 Academic Article GET IT